Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | FN-1501 |
| Synonyms | |
| Therapy Description |
FN-1501 inhibits FLT3, CDK2, CDK4, and CDK6, resulting in decreased downstream signaling and potentially leading to reduced tumor cell proliferation and tumor growth (PMID: 29357250). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| FN-1501 | FN1501|FN 1501 | CDK2 Inhibitor 31 CDK4 Inhibitor 18 CDK6 Inhibitor 6 FLT3 Inhibitor 69 | FN-1501 inhibits FLT3, CDK2, CDK4, and CDK6, resulting in decreased downstream signaling and potentially leading to reduced tumor cell proliferation and tumor growth (PMID: 29357250). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins | leukemia | sensitive | FN-1501 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with FN-1501 reduced phoshorylation of FLT3 and downstream STAT5, ERK, and AKT, induced apoptosis and cell-cycle arrest, and decreased proliferation in a human leukemia cell line harboring a FLT3-ITD mutation in culture, and induced tumor regression in xenograft models (PMID: 29357250). | 29357250 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03690154 | Phase I | FN-1501 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors | Terminated | USA | AUS | 0 |